$GLUE (MONTE ROSA THERAPEUTICS) — 8-K: Monte Rosa earns $50M milestone as Novartis starts Phase 2 for MRT-6160 in Sjögren’s disease

Novartis has initiated a Phase 2a/b randomized, double-blind, placebo-controlled, multi-center trial of VAV1-directed molecular glue degrader MRT-6160 (DDY391) in participants with Sjögren’s disease. Monte Rosa will receive a $50 million milestone payment from Novartis based on the first patient visit. The study will evaluate efficacy, safety, and tolerability of up to 52 weeks of treatment to support dose selection for Phase 3. Monte Rosa remains eligible for additional Phase 2 study initiation milestones under the global exclusive development and commercialization license agreement.

Novartis has initiated a Phase 2a/b randomized, double-blind, placebo-controlled, multi-center trial of VAV1-directed molecular glue degrader MRT-6160 (DDY391) in participants with Sjögren’s disease.